Differences in the presentation and progression of Parkinson’s disease by sex

Introduction

The prevalence of Parkinson’s disease (PD) is 1.5 −2.0 times higher in men than in women. This discrepancy suggests that there be sex-associated factors that modify the disease process. Identifying the interplay between sex and the disease has the potential to develop disease-modifying therapy as well as to inform patient management and the planning of more efficient clinical trials. Researchers have investigated the sex-associated differences in phenotypes among patients with PD.¹ Male PD patients were reported to have more akinesia/rigid features,² cognitive impairment,^3,4 and rapid eye movement sleep behavioral disorder.^5,6 On the other hand, depression,^7–10 and dyskinesia ^7,11–13 were documented to occur more frequently in female patients. However, these studies were generally small in sample size and predominantly done in a cross-sectional setting.

In this work, we analyzed longitudinal data from 12 PD cohorts representing 5,946 participants with a median of 3.7 years of follow-up. There were two objectives: (1) to identify the baseline differences between men and women in disease presentation and (2) to identify the influence of sex on longitudinal symptom trajectory. Further, we analyzed the Fox Insight dataset, an online-only Parkinson’s disease research cohort, to assess whether the observations in the longitudinal datasets were consistent in an independent dataset. Moreover, analyzing the data from both PD participants and non-PD participants of the Fox Insight dataset provided the opportunity to evaluate if there were any differences in the prevalence of self-reported outcomes between participants with and without PD. This analysis further illustrated that some of the differences may be inherited from general differences between males and females, while others are disease-specific.

Methods

Results

The cohort participants are summarized in Table 1. Participants in these cohorts were of different ages and in different stages of Parkinson’s disease, but overall they were in relatively early phases of their disease. The majority of the participants were of European descent. Interestingly, Fox Insight had more female participants than other cohorts and the ratio of females to males was especially high among non-PD participants in Fox Insight as previously described.²⁰

In total, we conducted 40 meta-analyses using the clinic-based longitudinal data, of which 3 were rejected by a test of heterogeneity with a significance level of 0.05. With the Bonferroni correction of multiple comparisons, we set our p-value (P) threshold as 0.05/37 =0.00135. Among these associations, 9 were significant and the direction and magnitude of associations of being female against being male are shown in Table 2 and Figure 1. (All meta-analysis results are in Supplemental Materials).

• Download figure
• Open in new tab

Figure 1: The forest plots for the sex differences in outcomes.

DATATOP, Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism; DIGPD, Drug Interaction with Genes in Parkinson’s Disease; HBS, Harvard Biomarkers Study; NET-PD_LS1, NIH Exploratory Trials in Parkinson’s Disease Large Simple Study 1; PARKFIT, ParkFit study; PARKWEST, The Norwegian ParkWest study; PDBP, Parkinson’s Disease Biomarker Program; PICNICS, Parkinsonism Incidence and Cognitive and Non-motor heterogeneity In Cambridgeshire; PPMI, Parkinson’s progression markers initiative; PreCEPT_PostCEPT, Parkinson Research Examination of CEP-1347 Trial and PostCEPT; PROPARK, Profiling Parkinson’s disease study; and UDALL_PENN, Morris K. Udall Centers for Parkinson’s Research.

P, non-adjusted p-values; I_sq, I² statistic; QEp, test of heterogeneity.

Female PD patients were less likely to develop cognitive impairment over time (HR 0.70 [0.59, 0.83], P = 4.8E-5). The stronger association was observed when we adjusted for years of education. (HR 0.63 [0.53, 0.76], P = 4.3E-7, Supplemental Material). Also, the baseline MoCA scores were higher in female patients (0.63 [0.27, 1.00]) while baseline MMSE score was not significantly different between sexes (P = 0.97, Supplemental Materials).

Female patients had a higher rate of developing dyskinesia (HR 1.29 [1.16, 1.44]). To assess the impact of weight, BMI and medication on the association, we conducted ad-hoc analyses on a subset of data (PDBP, PPMI and NET_PD_LS1. 2281 participants) where height at baseline, weight at baseline, and medication at visits were recorded. We adjusted analyses for each of these factors. With weight adjustment the association was no longer significant (P = 0.059), while the magnitude of the association became larger when adjusted for levodopa dosages or levodopa equivalent dosages.

Adjusting for BMI did not substantially change the magnitude of the association (Beta: from 0.285 to 0.250) and the sex difference was still significant. (Supplemental Materials). Consistent with the higher incidence rate of dyskinesia in female patients, prevalent female PD patients in non de novo cohorts also had more dyskinesia at baseline.

Activities of daily living, captured in the UPDRS Part II score, was better in female PD patients in the baseline analysis (--0.12 [−0.18, −0.06] in z score), and the progression rate was less in female patients (−0.14 [−0.20, −0.08] in z score per year). A more detailed analysis of the forest plots of the UPDRS Part II scores at baseline showed that the associations between sex and UPDRS Part II were not apparent among the de novo cohorts but rather driven by the differences observed in the non-de novo cohorts(Figure 1). While we did not find significant sex-associated differences in progression rate in UPDRS Part I/III/IV, the rate of change in the total scores of UPDRS were significantly milder in female patients (−0.11 [0.16, −0.06] per year in z score). When only considering the de novo cohorts, they reported similar results-progression rate was slower in female patients (−0.14 [−0.21, −0.07] in z score per year, P = 2.6E-5, Supplemental Materials).

Finally, female patients also had lower scores on the UPDRS Part III and the UPDRS total score compared to males in the baseline analyses.

In the analyses of similar phenotypes within the Fox Insight dataset (Table 3), we generally confirmed the results of the longitudinal dataset analyses. In the Fox Insight dataset analysis, the interaction terms between sex and disease duration indicated the average sex-associated differences in the longitudinal trajectories for the outcomes. For example, the positive association with the interaction and PDAQ-15 meant that, in the Fox Insight dataset, the scores of PDAQ-15 in female patients when compared with that in males were higher (i.e., better cognition-related instrumental functional abilities) among patients with longer disease durations. To illustrate this, we visualized the sex differences stratified by disease duration (supplemental materials). The result is consistent with that of the longitudinal dataset analysis that female patients had a lower risk of developing cognitive impairment during the course. Similarly, the results from the Fox Insight dataset were consistent with a higher rate of developing dyskinesia; and the lower scores and a slower deterioration rate in UPDRS Part II in female patients, as observed in the longitudinal analyses.

In addition, null differences between male and female patients in presentation and progression of wearing off, depression, and hyposmia were also supported in the Fox Insight dataset. In contrast, loss of the sense of smell/taste was significantly more frequently reported in males in the controls. Having PD might diminish the general sex difference in this phenotype. Single question answers for RBD and some NMSQuest questionnaire regarding “difficult to stay awake” (NMSQ_awake), “difficulty in getting to sleep” (NMSQ_Sleep), “feeling sad, low or blue” (NMSQ_feel), and NMSQ_Constipation were significantly different by sex in the Fox Insight dataset. The prevalence of similar outcomes such as pRBD, daytime sleepiness, insomnia, depression and constipation were not significantly associated with sex in the meta-analyses of 12 longitudinal cohorts. However, the test for these associations give raw p-values less than 0.05 with the same directions as the Fox Insight results. So it may be that there are sex-phenotype associations but the primary analyses didn’t have a large enough sample size to detect these. Of note, all of these sex-phenotype associations among PD participants in Fox Insight were also significant among non-PD participants. In addition, based on the test of homogeneity between the results from PD and non-PD participants, there was no evidence that the magnitude of these associations were different between PD and non-PD participants.

Discussion

We analyzed clinic-based longitudinal data from 5,946 participants and meta-analyzed the difference in presentation and progression of phenotypes between men and women with PD. We also used web-based online cohorts and analyzed data from 28,809 PD patients and 10,556 non-PD to confirm our results. The current results suggest that female PD patients develop dyskinesia early, progress more slowly with respect to activities of daily living (ADL) restrictions and are less likely to develop cognitive impairment. For some non-motor symptoms asked in online questionnaires (such as pRBD, daytime sleepiness, insomnia, depressive mood and constipation), we found significant sex-associated differences among PD participants only in the Fox Insight dataset, but we could not identify clear PD-specific differences when comparing PD and non-PD participants for these associations.

Some studies have previously reported that female patients had more risk of developing earlier and more severe dyskinesia,^7,11 and longer duration of dyskinesia.¹². This is consistent with the faster development of dyskinesia among female patients and a greater rate of increase in UPDRS Part IV scores in our study. The reason for this phenomenon is not fully understood, but relatively higher levodopa dosages according to body weight in females may be partially responsible.¹³ Our ad-hoc analyses also suggested the importance of body weight on the association between sex and early development of dyskinesia.

Regarding the impact on activities of daily living, contradictory results have been reported previously. Two studies evaluated patients who undertook the surgical treatment: one study observed no difference in UPDRS Part II between males and females, while the other reported females had worse scores. In their studies, females had a longer duration of the disease, which may have affected the results. Another cross-sectional study also reported worse UPDRS Part II in female patients.⁷ They reported that among 5 categories of overall ADL capacity, having the most severe 2 categories was more frequent in females using a chi-square test while our analyses used UPDRS Part II and multiple regression models. These different outcome measurements and statistical approaches may account for these different results.

The slower development of cognitive decline in female patients was reported from some longitudinal studies.^3,4,21 The executive and attention features were primarily affected in PD. We observed the discrepancy between MoCA and MMSE in the baseline analyses and this discrepancy may be partly because MoCA is more sensitive in detecting executive dysfunction than MMSE.²². In contrast, the longitudinal differences in the rates of decline in MoCA or MMSE were not significantly different by sex in our data. Interestingly, MoCA scores were sometimes reported to be higher in healthy aging women than men.^23–25 The slower development of cognitive impairment in females may in part reflect their relative high baseline ability in the areas susceptible for Parkinson’s disease.

Several associations reported previously were not observed in the current data. pRBD was reported to be more prevalent in males with PD,^5,6 while some disagree.^26,27 We, too, were unable to confirm the association in the current longitudinal dataset. Although the prevalence of pRBD detected by single question screening was higher in male patients in the Fox Insight dataset, the similarly higher prevalence of pRBD in non-PD male participants raises questions as to the PD-specific nature of this association. Female PD patients were more depressed according to previous reports.^7–10 We did not confirm this sex-associated difference in presentation and progression in our longitudinal data or the Fox Insight dataset. However, female PD patients expressed a depressive mood more frequently than male patients in response to the related NMSQuest question (‘feeling sad, ‘low’ or ‘blue’) in the Fox Insight dataset. But again, the magnitude of the associations was not different between PD and non-PD participants, indicating that the sex difference in this outcome may be not PD-specific.

There are some limitations to the current work. Fox Insight is an online-only cohort and inherently different from a clinic-based cohort; however, our analyses were mostly consistent across these two different settings. Also, because the study participants were almost all of European descent, it will be important to test the generalizability of these observations across different ancestrally distinct groups. In this study, we focused on the overall associations between sex and phenotypes and did not separate the biological mechanisms from environmental mechanisms. We believe that it will be important to examine the potential effects of environmental factors such as estrogen usage, history of pregnancy, tobacco use, and pesticide exposure, that may contribute to the differences between male patients and female patients.

Despite some limitations, the current work has some important meanings. First, the total number of participants in our longitudinal analysis was one of the largest studied. Second, although each study had different cohort characteristics, we controlled for heterogeneity and multiple comparisons to detect robust signals. Indeed, most of these associations between sex and disease presentation/progression were consistent with analyses in the independent Fox Insight dataset. Third, our results could be generalized to PD patients across various disease stages in different contexts given the range of studies incorporated. Fourth, by comparing PD with non-PD individuals, we obtained an insight into whether sex-associated phenotypes in PD were disease-specific or rather reflecting general differences by sex. Finally, female PD patients have been an underrepresented population in clinical trials.² The current work emphasizes the importance of recognizing gender bias in developing a treatment for Parkinson’s disease in the real world.

In conclusion, we observed that female PD patients were earlier in developing dyskinesia in their disease course and progressed more slowly with respect to cognitive deficits and problems with ADL compared to male PD patients. The associations were mostly consistent across the different longitudinal cohorts and the online survey.